LCAT and Cholestatic liver disease: ApoA-I and apoA-II, major apolipoproteins that are carried by HDL, have been described to be decreased in cholestatic liver diseases together with impaired HL, lipoprotein lipase (LPL), and LCAT activities [9,49].